Clarity Pharmaceuticals has signed a supply agreement with Nusano for copper-67 (Cu-67).
The agreement is effective as of October 16 and is for an initial period of three years, with automatic renewal for successive two-year periods. Under its terms, Nusano will produce Cu-67 radioisotopes at its 190,000 sq-ft facility in West Valley City, UT, which will open in late 2025. Production of Cu-67 is expected to begin in mid-2026.
Nusano is positioned to regularly supply Cu-67 for both Clarity's clinical trials and commercial use based on the ease of production and readily available target material. Nusano is setting up its own enriched stable isotope production for Cu-67 starting materials in the near future.
The agreement further expands Clarity's network of U.S.-based suppliers, which include NorthStar Medical Radioisotopes and Idaho State University's Idaho Accelerator Center.